Edesa Biotech Revenue and Competitors

Markham, ON CAN

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Edesa Biotech's estimated annual revenue is currently $3.6M per year.(i)
  • Edesa Biotech's estimated revenue per employee is $155,000

Employee Data

  • Edesa Biotech has 23 Employees.(i)
  • Edesa Biotech grew their employee count by 15% last year.

Edesa Biotech's People

NameTitleEmail/Phone
1
VP Research And DevelopmentReveal Email/Phone
2
VP, Corporate AffairsReveal Email/Phone
3
Director Business DevelopmentReveal Email/Phone
4
Director Clinical OperationsReveal Email/Phone
5
Research And Development ManagerReveal Email/Phone
6
Research And Development AssociateReveal Email/Phone
7
Research and Development AssociateReveal Email/Phone
8
Research And Development AssociateReveal Email/Phone
9
Senior Research And Development AssociateReveal Email/Phone
10
Research And Development AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.7M9-72%$39.4MN/A
#2
$0.9M11-83%$23.8MN/A
#3
$87.6M5656%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$7.8M50-68%N/AN/A
#6
$13.5M8730%N/AN/A
#7
$17.8M115-6%N/AN/A
#8
$0.9M11-39%N/AN/A
#9
$13.6M88-20%$86MN/A
#10
$20M129-12%N/AN/A
Add Company

What Is Edesa Biotech?

Founded in 2015, Edesa Biotech brings innovative new treatments for dermatological and anorectal diseases. Late-stage prescription drugs developed by Edesa Biotech aim to help patients who experience limited treatment options. Edesa Biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$3.6M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Edesa Biotech News

2022-04-19 - Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

TORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on...

2022-04-17 - -$0.37 Earnings Per Share Expected for Edesa Biotech, Inc ...

Several hedge funds and other institutional investors have recently bought and sold shares of EDSA. UBS Group AG grew its stake in Edesa Biotech...

2022-04-13 - Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa Biotech is developing two product candidates aimed at improving the quality of life of ACD patients and also saving the lives of thousands...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M23-38%N/A
#2
$4.7M25-7%N/A
#3
$2.5M25N/AN/A
#4
$3.7M250%N/A
#5
$2.5M260%N/A